MFDS — authorised 31 July 2014
- Marketing authorisation holder: BOEHRINGER INGELHEIM
- Status: likely_approved
🇰🇷 Striverdi Respimat in South Korea
MFDS authorised Striverdi Respimat on 31 July 2014
Marketing authorisation
Striverdi Respimat in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Respiratory approved in South Korea
Frequently asked questions
Is Striverdi Respimat approved in South Korea?
Yes. MFDS authorised it on 31 July 2014.
Who is the marketing authorisation holder for Striverdi Respimat in South Korea?
BOEHRINGER INGELHEIM holds the South Korean marketing authorisation.